ReviewJournal of immunology research2026
Natural Killer Cells in Uterine Adenomyosis: Immunological Mechanisms and Therapeutic Perspectives.
Review in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Natural Killer Cells in Uterine Adenomyosis: Immunological Mechanisms and Therapeutic Perspectives.Journal of immunology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Uterine adenomyosis (AM), a common gynecological disorder, is characterized by the invasion of endometrial glands and stroma into the myometrium, resulting in chronic pelvic inflammation and severe pain. This condition not only adversely affects patients' quality of life but also correlates with diminished fertility. Recent findings underscore the critical role of natural killer (NK) cells in the pathophysiology of AM. As a vital component of innate immunity, NK cells are responsible for identifying and eliminating abnormal cells, and functional alterations of NK cells may contribute to the progression of this disease. Although existing research has suggested preliminary associations between NK-cell dysfunction and AM, the exact mechanistic pathways and their clinical implications are still not fully elucidated. This review comprehensively explores the involvement of NK cells in AM, emphasizing their functional adaptability within the immune microenvironment, interactions with cytokine networks, and potential for therapeutic targeting. Furthermore, we critically assess the translational hurdles and propose a strategic framework for implementing NK cell-based immunomodulatory approaches in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.